title: Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications.
abstract: Recent guidelines on rheumatoid arthritis (RA) point to the importance of achieving remission as soon as possible during the course of the disease. The appropriate use of antirheumatic drugs is critical, particularly in early RA patients, before 24 weeks, since this is a 'window of opportunity' for treatment to modify disease progression. A treat-to-target strategy added to an aggressive therapeutic approach increases the chance of early remission, particularly in early RA patients. We conducted an overview of current therapeutic strategies leading to remission in early RA patients. We also provide interesting predictive factors that can guide the RA management strategy with regard to disease-modifying treatment and/or drug-free remission.
authors: Department of Rheumatology, School of Medicine, University of Los Andes, Santiago, Chile.
authors: Francisco
authors: F
authors: Espinoza
authors: Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Lapeyronie, Montpellier, France.
authors: Sylvie
authors: S
authors: Fabre
authors: Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Lapeyronie, 371, avenue du doyen Gaston Giraud, 34295 Montpellier, France.
authors: Yves-Marie
authors: YM
authors: Pers
keywords: disease-modifying antirheumatic drugs; early rheumatoid arthritis; predictive factors; remission; rheumatoid arthritis